Biotech Companies Deploy Extreme Survival Tactics Amid Funding Crisis

Biotech industry faces severe cash crisis as one-third of companies operate with less than 12 months of funding remaining

Three Key Facts

• At least 11 biotech firms have shuttered in 2025 due to limited IPO opportunities, restricted financing, and regulatory uncertainty forcing companies to adopt unprecedented survival strategies.
• Over one-third of biotechs have less than a year of cash remaining while only 18% maintain more than five years of operating funds, down from 24% in 2021.
• Biotech sector revenues grew 6.8% to $205 billion in 2024 despite widespread cost-cutting measures including 70% salary reductions and acquisitions of unrelated businesses like waste management.

Introduction

Biotech companies are deploying increasingly unconventional strategies to survive a punishing funding environment that has already claimed nearly a dozen firms this year. From acquiring waste management businesses to slashing executive salaries by 70%, the industry’s survival tactics reflect the severity of a cash crunch affecting companies across all development stages.

The biotech bear market has forced even established firms to abandon traditional business models. Companies now pursue revenue streams far outside their core competencies while simultaneously cutting operational expenses to extend their cash runways in an increasingly selective funding landscape.

Key Developments

Windtree Therapeutics exemplifies this trend by acquiring a Michigan waste management business alongside securing rights to purchase a 436-unit residential property in Houston. The Pennsylvania-based biotech aims to establish consistent revenue streams while maintaining its drug development pipeline.

Shuttle Pharmaceuticals in Maryland chose salary reductions over layoffs, cutting compensation by 70% across all staff levels including the C-suite. The company continues developing multiple therapeutics, with one candidate advancing through phase 2 trials for glioblastoma treatment.

CEO personal investments have become another lifeline strategy. Amro Albanna of Aditxt loaned his company $233,000 at 7.5% annual interest, while NKGen Biotech’s Paul Song invested $2.65 million of personal funds to support operations and a phase 1/2 Alzheimer’s cell therapy trial.

Market Impact

The S&P Biotechnology Select Industry Index remains 52% below its February 2021 pandemic peak, illustrating sustained investor skepticism toward biotech valuations. Early-stage venture capital deployment has shown modest recovery, rising from $12 billion in 2023 to $15 billion in 2024, though investors demonstrate heightened selectivity.

Biologics attracted $1.6 billion in Seed and Series A investments during Q1 2025, with an additional $3.4 billion in licensing upfronts. Small molecules secured $610 million in early-stage funding and $696 million in licensing deals, indicating continued investor preference for established therapeutic modalities over riskier approaches.

Recent workforce reductions highlight operational pressures across the sector. RallyBio announced 40% staff cuts despite reporting improved quarterly losses, while Arvinas eliminated 131 positions representing one-third of its workforce to streamline operations.

Strategic Insights

The current environment has created a stark divide between well-capitalized biotechs and those facing existential threats. Companies with robust financial backing can capitalize on distressed asset acquisitions, while cash-strapped firms resort to increasingly desperate measures to maintain operations.

Portfolio consolidation has emerged as a primary survival strategy, with firms focusing resources on their highest-potential assets while divesting or shelving secondary programs. This approach often accompanies operational restructuring designed to reduce fixed costs and extend cash runways.

The shift toward non-core business acquisitions represents a fundamental departure from traditional biotech models. Companies historically focused exclusively on drug development now pursue diverse revenue streams, acknowledging that scientific innovation alone cannot guarantee survival in the current market.

Expert Opinions and Data

Industry analysis reveals the severity of the cash crisis facing biotech companies. According to Fierce Biotech, the unusual strategies reflect broader market constraints that have fundamentally altered company behavior patterns.

EY’s 2025 Biotech Beyond Borders report confirms that more than one-third of biotechs maintain less than twelve months of operating cash. The percentage of companies with over five years of cash reserves declined from 24% in 2021 to 18% in 2024, indicating widespread financial pressure.

Despite operational challenges, the sector maintained growth momentum with R&D expenditures increasing nearly 12% year-over-year. This sustained investment in innovation demonstrates industry commitment to long-term development goals even as companies implement severe cost-cutting measures.

Syncona, a London-based biopharma venture capital firm, has adapted its strategy to focus on biotechs positioned for near-term returns rather than early-stage investments. The firm manages a $1.03 billion portfolio across 14 companies, with significant exposure to clinical and commercial-stage assets.

Conclusion

The biotech industry’s survival strategies have evolved beyond traditional cost management to include fundamental business model pivots and extreme financial measures. Companies now balance scientific advancement with immediate revenue generation, often through ventures completely unrelated to their core therapeutic focus.

The current environment rewards companies with diversified funding sources and flexible operational structures while punishing those dependent solely on traditional venture capital or public market access. These market dynamics are reshaping biotech business models and may permanently alter how companies approach financial sustainability alongside drug development.